WeVote
Log In

Bill

Bill

A 2983

Provides sales and use tax exemption for purchases of rapid or laboratory tests for purposes of detecting infections.

2026-2027 Regular Session Introduced by Erik Peterson

New Jersey bill exempts rapid and laboratory infection detection tests from sales tax, reducing testing costs but decreasing state revenue.

Introduced, Referred to Assembly Health Committee
0
WeVote Research Nonpartisan
Bill Summary · A 2983

Legislative bill overview

Bill A 2983 would exempt rapid diagnostic tests and laboratory tests used to detect infections from New Jersey's sales and use tax. This applies to both retail purchases of over-the-counter rapid tests (like COVID-19 or flu tests) and laboratory testing services. The exemption would reduce the final cost of these tests to consumers and medical providers.

Why is this important

Diagnostic testing is critical for early infection detection, disease containment, and public health response. Tax exemptions lower financial barriers to testing, potentially increasing utilization rates during outbreaks. However, this reduces state tax revenue and raises questions about which health products deserve preferential tax treatment.

Potential points of contention

  • Revenue impact: The bill doesn't specify expected fiscal costs to the state, making it difficult to assess budget implications
  • Scope ambiguity: It's unclear whether "laboratory tests" includes all infectious disease testing (blood tests, cultures, etc.) or only specific categories, and whether this covers private lab companies or all providers
  • Equity of exemptions: Questions about why infection tests merit exemption while other preventive health items (vaccines, first aid supplies) may not, and whether this primarily benefits those who can afford testing

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.